GolezarSRamezani TehraniFKhazaeiS, et al.The Global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric2019; 22(4): 403–411.
2.
DovomMRBidhendi-YarandiRMohammadK, et al.prevalence of premature ovarian insufficiency and its determinants in Iranian population: Tehran lipid and glucose study. BMC Women’s Health2021; 21: 71.
3.
LuborskyJLMeyerPSowersMF, et al.Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod2003; 18: 199–206.
4.
Guidelines of European Society of Human Reproduction and Embryology (ESHRE). Management of Women with Premature Ovarian Insufficiency 2015. ESHRE.
5.
LimbrinoudakiIPachouSA. Panay et al premature ovarian insufficiency: a toolkit for the primary care physician. Climateric2021; 24(5): 425–437.
6.
HamodaH. The British menopause society and women's health concern recommendations on the management of women with premature ovarian insufficiency. Post Reproductive Health2017; 23(1): 22–35.
7.
StevensonCollinsJCPCollinsPHamodaH, et al.Cardiometabolic health in premature ovarian insufficiency. Climacteric2021; 24(5): 474–480.
8.
NguyenHHMilatFVincentAJ. New insights into the diagnosis and management of bone health in premature ovarian insufficiency. Climacteric2021; 24(5): 481–490.
9.
European Society of Human Reproduction and Embryology. Information for Women with Premature Ovarian Insufficiency. Strombeek-Bever, Belgium: European Society of Human Reproduction and Embryology. Patient Version, 2016.
10.
HughesIAHoukCAhmedSF, et al.Consensus statement on management of intersex disorders. Arch Disease Childhood2006; 91(7): 554–563.
ChaudhrySTadokoro-CuccaroRHannemaSE, et al.Frequency of gonadal tumours in complete androgen insensitivity syndrome (CAIS): A retrospective case-series analysis. J Pediatric Urology2017; 13(5): 498–e6.
13.
KoJKYKingTFJWilliamsL, et al.Hormone replacement treatment choices in complete androgen insensitivity syndrome: an audit of an adult clinic. Endocr Connections2017; 6(6): 375–379.
14.
HuangHWangCTianQ. Gonadal tumour risk in 292 phenotypic female patients with disorders of sex development containing Y chromosome or Y-derived sequence. Clin Endocrinol2017; 86: 621–627.
